Abstract:Background & aims: Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common liver diseases worldwide and is characterized by multi-tissue insulin resistance. The effects of a 10-month energy restriction and exercise intervention on liver histology, anthropometrics, plasma biochemistries, and insulin sensitivity were compared to standard of care (control) to understand mechanisms that support liver health improvements. Methods: Following medical diagnosis of MASH, individuals were randomized to treatment (n = 16) or control (n = 8). Liver fat (magnetic resonance spectroscopy), 18-hour plasma biochemical measurements, and isotopically labeled hyperinsulinemic-euglycemic clamps were completed pre- and post-intervention. Body composition and cardiorespiratory fitness (VO2peak) were also measured mid-intervention. Those in the treatment group were counseled to reduce energy intake and completed supervised, high-intensity interval training (3x/week) for 10 months. Controls continued physician-directed care. Results: Treatment induced significant (p <0.05) reductions in body weight, fat mass, and liver injury, while VO2peak (p <0.05) and non-esterified fatty acid suppression (p = 0.06) were improved. Both groups exhibited reductions in total energy intake, hemoglobin A1c, hepatic insulin resistance, and liver fat (p <0.05). Compared to control, treatment induced a two-fold increase in peripheral insulin sensitivity which was significantly related to higher VO2peak and resolution of liver disease. Conclusions: Exercise and energy restriction elicited significant and clinically meaningful treatment effects on liver health, potentially driven by a redistribution of excess nutrients to skeletal muscle, thereby reducing hepatic nutrient toxicity. Clinical guidelines should emphasize the addition of aerobic exercise in lifestyle treatments for the greatest histologic benefit in individuals with advanced MASH. Impact and implications: The mechanisms that underpin histologic improvement in individuals with metabolic dysfunction-associated steatohepatitis (MASH) are not well understood. This study evaluated the relationship between liver and metabolic health, testing how changes in one may affect the other. We investigated the effects of energy restriction and exercise on the association between multi-tissue insulin sensitivity and histologic improvements in participants with biopsy-proven MASH. For the first time, these results show that an improvement in peripheral (but not hepatic) insulin sensitivity and systemic markers of muscle function (i.e. cardiorespiratory fitness) were strongly related to resolution of liver disease. Extrahepatic disposal of substrates and improved fitness levels supported histologic improvement, confirming the addition of exercise as crucial to lifestyle interventions in MASH. Clinical trial number: NCT03151798.

S1768 The Efficacy of GLP-1 Agonists in the Management of MASH in an Appalachian Cohort

The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis

The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic- Dysfunction Associated Steatohepatitis

Incretin-based investigational therapies for the treatment of MASLD/MASH

GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells

Beneficial effects of MGL‐3196 and BAM15 combination in a mouse model of fatty liver disease

Treating metabolic dysfunction‐associated steatohepatitis: The fat‐trimming FGF21 approach

Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)

Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials

Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: A prospective cohort study

FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction-Associated Steatohepatitis and Beyond

Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists

Current Progress and Challenges in the Development of Pharmacotherapy for Metabolic Dysfunction‐Associated Steatohepatitis

Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease

An insight into the updated pharmacotherapy of metabolic-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatohepatitis (MASH) in lean individuals: a review

Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis

New and emerging treatments for metabolic dysfunction-associated steatohepatitis

Diabetes as a risk factor for MASH progression

Genetic Evidence for GLP‐1 and GIP Receptors as Targets for Treatment and Prevention of MASLD/MASH

Histological improvements following energy restriction and exercise: The role of insulin resistance in resolution of MASH

S1981 A Systematic Review Comparing GLP-Agonists and Resmetirom for Improving Fibrosis among Patients With Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)